From evolving China deal dynamics and prolonged job searches to the growing push for AI-driven drug repurposing, explore how shifts in BioPharma are redefining innovation, hiring, and strategy across the sector. Don’t miss the latest:
Can AI Crack Pharma Repurposing? FDA Looking at New Uses for Existing Therapies
Source: PharmaVoice
The FDA is ramping up efforts to identify new uses for existing drugs, aiming to replicate past successes in drug repurposing and expand treatment options where needs remain unmet. With vast amounts of underused clinical data available, AI and machine learning are emerging as key tools to uncover hidden insights and accelerate this process. The initiative signals a broader push for more data-driven, efficient drug development while unlocking untapped value in older therapies.
No Longer a Bargain Pool. Chinese BioTechs Command Higher Premiums
Source: BioSpace
Deal dynamics between Chinese BioTechs and global pharma companies are shifting, with Chinese BioTechs demanding higher upfront payments while Big Pharma moves toward broader platform deals. As pricing pressures rise and patent expirations take hold, large drugmakers are increasingly turning to Chinese BioTechs for faster, more cost-effective innovation that can help replenish their pipelines. At the same time, these partnerships offer Chinese BioTechs a pathway to global expansion and validation of their scientific capabilities.
The Long Wait. BioPharma Job Searches Often Take at Least 6 Months
Source: BioSpace
Biotech and pharma job searches are stretching longer, with over half of candidates looking for six months or more and more than a quarter searching for over a year. Frustrations are mounting, including job ghosting, questionable postings, and increasingly rigid or competitive hiring requirements. As layoffs continue and response rates drop, many professionals are accepting roles below their experience level just to stay employed.
